| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
thyroid hormone receptorα; thyroid hormone receptor β-1
Liothyronine sodium (active component: T3) acts on beta 1 thyroid hormone receptor (TRβ1)[1] Liothyronine sodium (active component: T3) binds to human beta 1 thyroid hormone receptor (hTRβ1)[2] |
|---|---|
| ln Vitro |
Liothyronine (T3, 100 nM) sodium encourages hepatocarcinoma cells with overexpressed TRβ1 to proliferate[1]. When ligothyronine sodium binds to the human β1 thyroid hormone receptor (hTRβ1), it modifies the receptor's structure. Growth, differentiation, and metabolic effects are all regulated by lithyronine sodium [2].
In poorly differentiated human hepatocarcinoma cells overexpressing TRβ1, treatment with Liothyronine sodium (active component: T3) stimulated cell proliferation[1] Binding of Liothyronine sodium (active component: T3) to hTRβ1 induced conformational changes in hTRβ1[2] |
| ln Vivo |
The experiment for detecting conformational changes of hTRβ1 induced by Liothyronine sodium (active component: T3) involved purification of recombinant hTRβ1 protein, incubation of T3 with hTRβ1 at a specific temperature and time, and detection of conformational changes using a specific method[2]
|
| Enzyme Assay |
To understand the structural basis in the hormone-dependent transcriptional regulation of human beta 1 thyroid hormone receptor (h-TR beta 1), we studied the conformational changes of h-TR beta 1 induced by binding of 3,3',5-triiodo-L-thyronine (T3). h-TR beta 1 was treated with trypsin alone or in the presence of T3, thyroid hormone response element (TRE) or T3 together with TREs. Without T3, h-TR beta 1 was completely digested by trypsin. Binding of TREs had no effect on the tryptic digestion pattern. However, T3-bound h-TR beta 1 became resistant to tryptic digestion and yielded trypsin-resistant peptide fragments with molecular weight of 28,000 and 24,000. Chymotryptic digestion also yielded a T3-protected 24 Kd peptide fragment. Using anti-h-TR beta 1 antibodies and amino acid sequencing, the 28 Kd fragment was identified to be Ser202-Asp456. The 24 Kd tryptic fragments were found to be Lys239-Asp456 and Phe240-Asp456. The 24 Kd chymotryptic fragment was identified to be Lys235-Asp456. The structural changes as a result of T3 binding could serve as a transducing signal to modulate the gene regulating activity of h-TR beta 1[2].
|
| Cell Assay |
Thyroid hormone depleted (Td) serum is prepared. Hepatocarcinoma cell growth in methylcellulose is carried out. Cells are plated at a density of 3 × 104 cells/60 mm dish on day 0 and incubated in medium containing 5% regular serum, 5% Td or 5% Td and 100 nM T3. This is done to ascertain the impact of Liothyronine (T3) on the growth of cells. Three weeks after the initial plating, the methylcellulose colony formation is scored[1].
The cell experiment for Liothyronine sodium (active component: T3) included transfection of TRβ1 expression vector into poorly differentiated human hepatocarcinoma cells to establish TRβ1-overexpressing cell lines, culture of cells in medium containing T3 for a specific duration, and detection of cell proliferation using a specific method[1] |
| References |
|
| Additional Infomation |
Sodium triiodothyronine (TTI) is the sodium salt of triiodothyronine. It is considered more potent than levothyroxine, with a rapid onset of action (within hours) and a shorter duration of action, and is therefore used to treat hypothyroidism, especially hypothyroid coma. It contains 3,3',5-triiodo-L-thyroxine salt. TTI is the sodium salt form of triiodothyronine, the synthetic form of the levorotatory isomer of the natural thyroid hormone triiodothyronine (T3). TTI binds to the nuclear thyroid receptor, which in turn binds to the thyroid hormone response element of the target gene. Therefore, TTI induces the expression of genes required for normal growth and development. TTI is more potent and has a faster onset of action than thyroxine (T4). Thyroid hormone T3 is normally synthesized and secreted by the thyroid gland, but in much smaller quantities than thyroxine (T4). Most T3 originates from the peripheral deiodination of T4 at the 5' position of the iodothyronine nucleus. Ultimately, the hormone transported and utilized by tissues is primarily T3. See also: Triiodothyronine triiodophosphate (with active fraction).
Sodium triiodothyronine triiodophosphate is a synthetic thyroid hormone whose active component T3 exerts its biological effects by binding to the thyroid hormone receptor; literature shows that T3 can promote the proliferation of human liver cancer cells overexpressing TRβ1, which may be related to the regulatory role of TRβ1 in the cell cycle process [1] The conformational change of hTRβ1 induced by sodium triiodothyronine triiodophosphate (active component: T3) is the basis for the receptor to recruit coactivators or co-inhibitors, thereby regulating the expression of downstream genes [2] |
| Molecular Formula |
C15H11I3NNAO4
|
|---|---|
| Molecular Weight |
672.9553
|
| Exact Mass |
672.771
|
| Elemental Analysis |
C, 26.77; H, 1.65; I, 56.57; N, 2.08; Na, 3.42; O, 9.51
|
| CAS # |
55-06-1
|
| Related CAS # |
Liothyronine;6893-02-3;Liothyronine sodium hydrate;345957-19-9;Liothyronine hydrochloride;6138-47-2
|
| PubChem CID |
23666110
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
563.5ºC at 760 mmHg
|
| Melting Point |
205 °C (dec.)(lit.)
|
| Flash Point |
294.6ºC
|
| LogP |
3.318
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
24
|
| Complexity |
408
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
IC1C(=C(C([H])=C(C=1[H])C([H])([H])[C@@]([H])(C(=O)[O-])N([H])[H])I)OC1C([H])=C([H])C(=C(C=1[H])I)O[H].[Na+]
|
| InChi Key |
SBXXSUDPJJJJLC-YDALLXLXSA-M
|
| InChi Code |
InChI=1S/C15H12I3NO4.Na/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22;/h1-4,6,12,20H,5,19H2,(H,21,22);/q;+1/p-1/t12-;/m0./s1
|
| Chemical Name |
sodium;(2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoate
|
| Synonyms |
Liothyronine; Cytomel; Tertroxin; Triiodothyronine; 3,5,3'-triiodothyronine; 3,3',5-Triiodo-L-thyronine; Tresitope; LIOTHYRONINE SODIUM; 55-06-1; Cytomel; Triostat; 3,3',5-Triiodo-L-thyronine sodium salt; Tertroxin; Basoprocin; Ibiothyron; Liothyronin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
0.1 M NaOH: ~12.5 mg/mL (~18.6 mM)
DMSO: ~5.6 mg/mL (~8.3 mM) H2O: < 0.1 mg/mL) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.71 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.71 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.71 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4860 mL | 7.4299 mL | 14.8597 mL | |
| 5 mM | 0.2972 mL | 1.4860 mL | 2.9719 mL | |
| 10 mM | 0.1486 mL | 0.7430 mL | 1.4860 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04115514 | Recruiting | Drug: Liothyronine Sodium (T3) (modified formulation) |
Lung, Wet Thyroid |
University of Minnesota | October 21, 2019 | Phase 2 |
| NCT01800617 | Completed | Drug: Liothyronine, Sodium | Hypothyroidism | Ipe, LLC | March 2013 | Phase 2 |
| NCT01153360 | Completed | Drug: liothyronine sodium Drug: placebo |
Non-thyroidal Illness Syndrome | Yonsei University | June 2010 | Not Applicable |
| NCT01581463 | Completed | Drug: Liothyronine, Sodium | Healthy | Ipe, LLC | April 2012 | Phase 1 |
| NCT02760056 | Completed | Drug: Liothyronine sodium Drug: Placebo |
Multiple Sclerosis | Oregon Health and Science University |
June 6, 2016 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
